Key clinical point: All patients with metastatic non–small cell lung cancer should be tested for targetable mutations/alterations.
Major finding: The 5-year overall survival for patients with ALK rearrangements now exceeds 40%.
Study details: A review of the literature on medical therapies for non–small cell lung cancer.
Disclosures: The review was supported in part by a grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center. Dr. Arbour reported serving as a consultant to AstraZeneca and nonfinancial research support from Novartis and Takeda. Dr. Riely reported grants and nonfinancial support from Pfizer, Roche/Genentech/Chugai, Novartis, Merck, and Takeda; a patent pending for an alternate dosing of erlotinib for which he has no right to royalties; and payments from the National Comprehensive Cancer Network to participate in a committee overseeing solicitation and selection of grants to be awarded by AstraZeneca.
Arbour KC and Riely GJ. JAMA. 2019;322(8):764-74.